Shilpa Medicare Limited Q4 FY26 Financials and Strategic Growth Initiatives

Shilpa Medicare Limited has announced its financial results for the fourth quarter and full financial year ending March 31, 2026. The board has approved a final dividend of Re. 0.60 per equity share. Key strategic highlights include an equity investment in a renewable energy firm, the restructuring of registered offices for several subsidiaries, and the appointment of new auditors for the upcoming fiscal year.

Financial Highlights

For the financial year ended March 31, 2026, the company reported robust performance. The standalone revenue from operations reached ₹59,703 lakh, while the consolidated revenue surged to ₹153,887 lakh. The consolidated profit after tax attributable to the owners stood at ₹24,333 lakh for the fiscal year. Auditors have issued an unmodified opinion on both standalone and consolidated financial statements.

Dividend Recommendation

The Board of Directors has recommended a final dividend of Re. 0.60 (60%) per equity share of face value Re. 1 each for the financial year 2025-26. The payout is subject to approval by shareholders at the upcoming Annual General Meeting and will be processed within the prescribed statutory timelines.

Strategic Renewable Energy Investment

The company is diversifying its operational energy sourcing. Wholly owned subsidiaries, including Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Pvt Ltd, and Shilpa Biocare Pvt Ltd, will collectively acquire a 28% equity stake in Neo Green Power Project Private Limited. The total group investment for this stake is ₹4.44 crore. This acquisition is designed to meet the captive power requirements for the subsidiaries’ operations.

Operational Reorganization

The company is shifting its registered office from Raichur, Karnataka, to the State of Maharashtra. This transition, which requires member approval via postal ballot, will also see the registered offices of several subsidiaries—including Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Private Limited, Shilpa Biocare Private Limited, and Sampra Holdings Private Limited—relocated to Maharashtra.

Governance and Audits

To ensure robust corporate governance for the 2026-27 fiscal year, the company has appointed M/s. V.J. Talati & Co. as Cost Auditors and M/s ANEJA ASSOCIATES as Internal Auditors. Additionally, Mr. Santosh Kumar Gunemoni, a Practicing Company Secretary, has been appointed as the Scrutinizer to oversee the postal ballot process regarding the office relocation.

Source: BSE

Previous Article

Jubilant Pharmova Reports Strong FY26 Growth with 14% Revenue Increase

Next Article

Endurance Technologies Strong Q4 FY26 Results with 37.3% Consolidated Revenue Growth